Department of Interventional Neuroradiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
Department of Interventional Neuroradiology, Hospital Universitario 12 de Octubre, Madrid, Spain.
J Neurointerv Surg. 2023 Jul;15(7):674-678. doi: 10.1136/neurintsurg-2022-018649. Epub 2022 May 31.
The Q Aspiration Catheter (MIVI Neuro) has demonstrated greater aspiration flow rates and ingestion forces compared with conventional catheters in vitro. The safety and performance of the Q Catheter was assessed using a direct aspiration first pass technique in patients with acute ischemic stroke at four neurointerventional centers in Spain.
We included adult patients who underwent mechanical thrombectomy between March 2019 and March 2020 using the Q Catheter as first-line therapy. Performance endpoints included final successful revascularization of the target vessel (defined as modified thrombolysis in cerebral infarction (mTICI) grade 2B/3), first pass revascularization, and overall Q Catheter revascularization. Safety endpoints were symptomatic intracranial hemorrhage (sICH), embolization to new territory (ENT), and procedural complications. Modified Rankin Scale (mRS) score and all-cause mortality were also assessed.
Forty-five subjects were enrolled. The Q Catheter successfully navigated to the lesion in 95.5% (43/45) of patients. Final successful mTICI 2B/3 revascularization was achieved in 93.3% (42/45), first pass mTICI 2B/3 revascularization with the Q Catheter was 55.3% (21/38), and overall with Q Catheter mTICI 2B/3 revascularization was 65.8% (25/38). Favorable clinical outcome of mRS 0-2 was achieved in 55.6% (25/45). There were no cases of ENT. sICH and mortality rates were 2.2% (1/45) and 13.3% (6/45), respectively.
In this multicenter, observational study, the Q Aspiration Catheter used as first-line therapy demonstrated a good and safe profile in terms of navigation, revascularization, and safety in patients with acute ischemic stroke.
与传统导管相比,Q 抽吸导管(MIVI 神经)在体外具有更大的抽吸流速和抽吸力度。在西班牙的四个神经介入中心,使用直接抽吸初次通过技术对急性缺血性脑卒中患者进行了 Q 导管的安全性和性能评估。
我们纳入了 2019 年 3 月至 2020 年 3 月期间使用 Q 导管作为一线治疗的机械血栓切除术的成年患者。性能终点包括目标血管的最终成功再通(定义为改良脑梗死溶栓(mTICI)分级 2B/3)、初次通过再通和整体 Q 导管再通。安全性终点为症状性颅内出血(sICH)、新区域栓塞(ENT)和程序并发症。改良 Rankin 量表(mRS)评分和全因死亡率也进行了评估。
45 名受试者入组。95.5%(43/45)的患者 Q 导管成功到达病变部位。93.3%(42/45)的患者最终获得成功的 mTICI 2B/3 再通,55.3%(21/38)的患者通过 Q 导管实现了初次通过 mTICI 2B/3 再通,65.8%(25/38)的患者通过 Q 导管实现了整体 mTICI 2B/3 再通。55.6%(25/45)的患者获得了 mRS 0-2 的良好临床结局。没有发生 ENT。sICH 和死亡率分别为 2.2%(1/45)和 13.3%(6/45)。
在这项多中心观察性研究中,作为一线治疗方法的 Q 抽吸导管在急性缺血性脑卒中患者的导航、再通和安全性方面表现出良好且安全的特征。